Observational Study of Rapid Sequence Intubation (RSI) Drug Delivery Using Intraosseous (IO) and Intravenous (IV) Access.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01486407|
Recruitment Status : Terminated (For poor enrollment)
First Posted : December 6, 2011
Last Update Posted : February 1, 2013
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||2 participants|
|Official Title:||An Observational Study of Intubating Conditions Comparing Intraosseous Vascular Access With Peripheral Intravenous Access for Drug Delivery in Rapid Sequence Intubation|
|Study Start Date :||February 2012|
|Actual Primary Completion Date :||December 2012|
|Actual Study Completion Date :||December 2012|
Intravenous (IV) drug delivery
patients on whom intravenous vascular access has been established for the purpose of rapid sequence intubation drug delivery.
Intraosseous (IO) drug delivery
Patients on whom intraosseous vascular access has been established for rapid sequence intubation drug delivery.
- Time from first drug delivery to operator-perceived sufficient relaxation to perform endotracheal tube placement [ Time Frame: during rapid sequence intubation procedure, average expected time frame 30 minutes ]
- Intubation difficulty using the intubation difficulty scale [ Time Frame: during rapid sequence intubation procedure, average expected time frame 30 minutes ]
- Operator satisfaction with intubating conditions using visual analog scale [ Time Frame: during rapid sequence intubation procedure, average expected time frame 30 minutes ]
- Failure rate of endotracheal intubation and requirement for alternative airway management methods [ Time Frame: during rapid sequence intubation procedure, average time frame 30 minutes ]
- Incidence of short-term catheter related complications for each technique [ Time Frame: during emergency department stay, average time frame 24 hours ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01486407
|United States, Texas|
|Christus Spohn Hospital Corpus Christi|
|Corpus Christi, Texas, United States, 78405|
|Texas Tech University Health Science Center El Paso|
|El Paso, Texas, United States, 79905|
|Principal Investigator:||Stephen W Borron, MD||Texas Tech University Health Science Center|